Methyl aminolevulinate
Metvixia (methyl aminolevulinate) is a small molecule pharmaceutical. Methyl aminolevulinate was first approved as Metvixia on 2004-07-27.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Clinical
Clinical Trials
79 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Actinic keratosis | D055623 | — | L57.0 | 5 | 4 | 12 | 9 | 16 | 44 |
| Keratosis | D007642 | — | — | 3 | 1 | 1 | 5 | 5 | 15 |
| Basal cell carcinoma | D002280 | — | — | 3 | 3 | 7 | 1 | 3 | 15 |
| Bowen's disease | D001913 | — | D00-D09 | 2 | — | 1 | 1 | 2 | 6 |
| Skin diseases | D012871 | — | L00-L99 | 1 | — | — | 1 | 1 | 3 |
| Cheilitis | D002613 | HP_0100825 | K13.0 | 1 | — | — | 1 | — | 2 |
| Connective tissue diseases | D003240 | EFO_1001986 | M35 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Basal cell neoplasms | D018295 | — | — | 2 | 3 | 6 | — | 2 | 11 |
| Carcinoma | D002277 | — | C80.0 | 2 | — | 1 | — | 1 | 4 |
| Skin aging | D015595 | EFO_0005422 | — | — | 1 | 1 | — | 1 | 3 |
| Squamous cell carcinoma | D002294 | — | — | — | — | 1 | — | — | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | — | 1 | — | — | 1 |
| Warts | D014860 | — | B07 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | 3 | — | — | 1 | 4 |
| Photochemotherapy | D010778 | — | — | 1 | 2 | — | — | — | 2 |
| Uterine cervical dysplasia | D002578 | EFO_1000910 | N87 | 1 | 1 | — | — | — | 1 |
| Cutaneous leishmaniasis | D016773 | — | B55.1 | — | 1 | — | — | — | 1 |
| Leishmaniasis | D007896 | EFO_0005044 | B55 | — | 1 | — | — | — | 1 |
| Vulvar neoplasms | D014846 | — | C51 | — | 1 | — | — | — | 1 |
| Squamous intraepithelial lesions | D000081483 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | 1 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | — | 1 |
| Wound infection | D014946 | — | — | 1 | — | — | — | — | 1 |
| Surgical wound infection | D013530 | — | — | 1 | — | — | — | — | 1 |
| Prostheses and implants | D019736 | — | — | 1 | — | — | — | — | 1 |
| Prosthesis-related infections | D016459 | EFO_1001406 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leg ulcer | D007871 | — | — | — | — | — | — | 1 | 1 |
| Rosacea | D012393 | — | L71 | — | — | — | — | 1 | 1 |
| Extramammary paget disease | D010145 | — | — | — | — | — | — | 1 | 1 |
| Mammary paget's disease | D010144 | — | C50 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methyl aminolevulinate |
| INN | _ |
| Description | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. It has a role as an antineoplastic agent, a photosensitizing agent, a prodrug and a dermatologic drug. It is functionally related to a 5-aminolevulinic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)CCC(=O)CN |
Identifiers
| PDB | — |
| CAS-ID | 33320-16-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1096562 |
| ChEBI ID | 724125 |
| PubChem CID | 157922 |
| DrugBank | DB00992 |
| UNII ID | 7S73606O1A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,078 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
93 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use